About UsInd Swift Group, a legendary forename in the world Class Pharmaceutical Industry who has broaden its horizons by plucking profound & sparkling footprints on multifarious diversified fronts, whilst going steadily and surely, scripting a success story filled with enviable milestones and pioneering breakthroughs and has subsequently emergent as a group with an annual turn over of 1000 Crore.
ORGANISATIONAL STRUCTURE-IND SWIFT GROUP
Ind Swift group, as pharmaceutical business model is one of India's largest manufacturer of high growth multi segment pharmaceutical finished dosage forms and API's (Active Pharmaceutical Ingredients).
Manufacturing of Pharmaceutical finished dosage are carried out at 7 state-of-the art manufacturing facilities which are second to the none are duly certified and approved by WHO GMP, spread over an area of 12, 00, 000 sq. ft. with manufacturing capacities confirming to stringent TGA/MHRA approvals; possessing an installed capacities of 3 billion units comprising tablets, capsules, Ointments, Injectable, Liquids & Dry Syrup (all latest formulations with a marketing network.
Our API section has spread over an area of 7 Lac sq. ft, carried out at 3 different state-of-th-art units approved by USFDA and E.U regulatory authorities with a marketing network spread over in 40 countries viz. Europe/USA/Middle East possessing 2 patented molecules with 11 molecules in offing It possesses 50% exports percentage. Ind Swift entered into bulk drugs with its own Research and Development facility and laboratories at Derabassi. Later on, those units got USFDA approval and got the process patents for Clarithromycin for US and allied markets and further five more patent drugs await clearance for the moment. A joint venture with Iran has also been signed for the manufacturing of Clarithormycin with construction underway and will start operations by the end 2008. The company has offices and supplies pharma drugs not only in India but overseas as well.
R & D (Research & Development)
Ind Swift is known for it's reverse engineering ability with highly focused R & D capabilities (duly approved by Department of Science & Technology, Govt. of India) and is equipped with state-of-the-art equipment, facilities and talented pool of scientists and Researchers.
A well accepted expertise in NDDS, in India and the world over.
A US patent for Clarie OD, with a market size of US$ 300 million.
Another patent for Fexofenadine ODT with a market size of US$ 2.5 billion.
Development of 10 new molecules with a market size of US$ 6 billion.
Ind Swift's efforts and achievements in taste masking of macrolides was India's first......... and remains the only feat of its kind in the country. The R &D department is also involved in creating international opportunities and alliances for CRAMS business, contributing significantly to the Company's profitability. It also offers complete support to international partners for preparing and filing dossiers for finished dosages. By taking giant strides on roads less traveled, Ind-Swift has become one of India's fastest growing pharmaceutical companies.
Apart from its existing plants in tax exempted zone of J&K and Baddi, duly certified and approved by WHO GMP, your company has successfully commissioned another Manufacturing facility at the same tax exempted zone and green plains of Baddi during the year. This new manufacturing facility inaugurated in August 2007, is for soft Gelatin Encapsulation with an annual capacity of 36 Crore and will not only make us almost self sufficient in soft gelatin manufacturing but will unquestionably dedicated a bit of spare capacities for contract manufacturing as well.
Company's manufacturing unit at Parwanoo has also been upgrades as per WHO Standards.
Company's Global Business Unit (GBU) at De |
Processing...
